JointHealth™ express March 18, 2014
Reminder: Patient input on treatment for psoriatic arthritis needed
Do you have psoriatic arthritis or care for someone who does? We want your valuable input.
On February 28, Arthritis Consumer Experts sent out a JointHealth™ express announcing that we are gathering patient input to submit to the Common Drug Review (CDR).
There is still time to get involved. The CDR continues to accept input on the manufacturer’s submission of ustekinumab (Stelara®) for the treatment of psoriatic arthritis from patients and their caregivers.
If you live with psoriatic arthritis or care for someone with the disease, please send us your input. Please provide your input by Friday, March 28, 2014, so that we may submit a report by the April 1 deadline.
Please contact us at info@jointhealth.org to provide your input or arrange for a phone interview.
Reminder: Patient input on treatment for psoriatic arthritis needed
Do you have psoriatic arthritis or care for someone who does? We want your valuable input.
On February 28, Arthritis Consumer Experts sent out a JointHealth™ express announcing that we are gathering patient input to submit to the Common Drug Review (CDR).
There is still time to get involved. The CDR continues to accept input on the manufacturer’s submission of ustekinumab (Stelara®) for the treatment of psoriatic arthritis from patients and their caregivers.
If you live with psoriatic arthritis or care for someone with the disease, please send us your input. Please provide your input by Friday, March 28, 2014, so that we may submit a report by the April 1 deadline.
Please contact us at info@jointhealth.org to provide your input or arrange for a phone interview.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.